Human Microbiome Project (HMP)

Program Initiatives

Developing a reference set of microbial genome sequences and preliminary characterization of the human microbiome

• This initiative will begin with the sequencing of up to 600 genomes from both cultured and uncultured bacteria, plus several non-bacterial microbes. Combined with existing and other currently planned efforts, the total reference collection should reach 1000 genomes.
• The initiative will continue with metagenomic analysis to characterize the complexity of microbial communities at individual body sites, and to determine whether there is a core microbiome at each site. Pilot studies will implement shallow and then deep 16S rRNA sequencing, progressing into deep metagenomic sequencing. Several body sites will be studied, including the gastrointestinal and female urogenital tracts, oral cavity, naso-pharyngeal tract, and skin.
• For more information and updates on this component of the project, visit http://hmp.nih.gov.

Relationship between disease and changes in the human microbiome

The second initiative includes a set of demonstration projects to determine the relationship between human health and changes in the human microbiome. The initiative will be implemented by investigator-initiated projects that can leverage the advances of the Human Microbiome Project to examine the relationship between changes in the human microbiome and diseases of interest.

• HMP Data Release and Resource Sharing Guidelines for Human Microbiome Project Data Production Grants

Development of new technologies

Taking full advantage of the decreased cost of sequencing to improve our knowledge of the human microbiome will require advances in microbial genomics technologies. The ability to generate whole genome sequences is currently limited to the relatively small class of microbes that can be cultured. In order to maximize the number of sequences available in the reference set, new techniques must be developed to culture or otherwise isolate for analysis currently unculturable organisms. In the long-term, methods for sequencing individual microbes or otherwise analyzing all of the members of complex populations will substantively advance this field.

Development of new tools for computational analysis

The data sets produced by metagenomic sequencing and related components will be very large and complex, requiring novel analytical tools for distilling useful information from vast amounts of sequence data, functional genomic data and subject metadata. In addition, if next generation sequencing platforms are used, they will produce large quantifies of sequence data that will need new analysis methods.

Establishing a Data Analysis and Coordinating Center (DACC)

The DACC will be a resource to find information about the project, along with its results and conclusions. Since the HMP, as a community resource project, is committed to rapid data release, the DACC will prove invaluable for coordination of data access and analysis. The DACC will have several specific functions:

• Track, store and distribute raw data, metadata and processed data
• Coordinate data analyses
• Develop data retrieval tools for the research community
• Coordinate development of metadata standards
• Establish a portal to display activities of international projects

Establishing a resource repository

A central repository is needed to store materials and reagents generated under the HMP including:

• Cultured organisms
• Amplified DNA from uncultured organisms
• Metagenomic DNA samples

The repository will make resources widely available to the scientific community at a reasonable cost and provide a newsletter to inform sample donors and interested members of the lay public about on-going project progress.

Ethical, legal and social implications (ELSI) of HMP research

The ethical, legal and social implications of HMP research will be studied including:

• Clinical and health implications (e.g. probiotic use)
• Potential forensic uses of microbiome profiles
• Bioterrorism and biodefense applications
• Uses of new technology driven by the HMP
• Ownership of one’s own microbiome and privacy issues

Up to Top